Key Market Indicator:
Ad-hoc news is mandatory information from listed companies that must be made available to investors. Depending on the occasion and content of the news, it can have an impact on the share price. The newsfeed covers a wide range of topics relevant to investor relations and is recommended as an important source of information before making an investment decision.
Wed, 15.04.2026
AIXTRON SE
THIS ANNOUNCEMENT, INCLUDING THE INFORMATION INCLUDED HEREIN, IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, WHETHER WHOLLY OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH, OR TO PERSONS IN ANY JURISDICTION TO WHOM, SUCH RELEAS [ … ]
Wed, 15.04.2026
Gerresheimer AG
Gerresheimer AG: Creditors agree to extend the due date for submitting the audited 2025 annual and consolidated financial statements
Duesseldorf, April 15, 2026. Gerresheimer AG (ISIN: DE000A0LD6E6, "Gerresheimer") has reached an agreement with its creditors regarding an extension of the due date for submitting the audited 2025 annual and consolid [ … ]
Wed, 15.04.2026
Formycon AG
Disclosure of inside information pursuant to Article 17 of Regulation (EU) No 596/2014
Formycon AG announces improved preliminary figures for the 2025 fiscal year and sets date for the publication of the annual financial statements
Group EBITDA of approx. € -4 million (vs. € -12 million) and adjusted EBITDA of approx. € -2 million (vs. € -7 milli [ … ]
Wed, 15.04.2026
FamiCord AG
FamiCord AG publishes preliminary figures for 2025 and outlook for 2026
Leipzig, 15 April 2026 – FamiCord AG closed the year 2025 with an overall consistently solid operational development and continued its path of increasing efficiency. This is the conclusion reached by the Management Board on the basis of the preliminary business figures availab [ … ]
Wed, 15.04.2026
MindMaze Therapeutics Holding SA
MindMaze Therapeutics Publishes 2025 Annual Report and Corporate Update
Positive real-world evidence results from multi-site program conducted with Vibra Healthcare
Established clinical and commercial foundation in neurological care
Advancement of U.S. commercial expansion and reimbursement strategy
Appointment of Zach Henderson as Chief Execut [ … ]
Tue, 14.04.2026
AIXTRON SE
AIXTRON SE increases FY 2026 guidance and reports preliminary Q1/2026 figures
Herzogenrath, April 14, 2026 – AIXTRON SE (FSE: AIXA, ISIN DE000A0WMPJ6) is increasing its guidance for fiscal year 2026 on the back of stronger than expected Optoelectronics equipment demand.
Preliminary order intake in the first quarter of 2026 turned out at appro [ … ]
Tue, 14.04.2026
Shelly Group SE
Publication of inside information according to Article 17 MARShelly Group reports preliminary group revenue for Q1 2026
Sofia / Munich, 14 April 2026 – Shelly Group SE (Ticker: SLYG / ISIN: BG1100003166) (“Shelly Group” / “the Company”) reported a year-on-year increase in revenue from Shelly devices and related services of approximately 26% to arou [ … ]
Tue, 14.04.2026
Private Equity Holding AG
NEWS RELEASE
Zurich, April 14, 2026
Net Asset Value as of March 31, 2026
As of March 31, 2026, the Net Asset Value (NAV) per share of Private Equity Holding AG (PEH) stood at EUR 157.10 (CHF 145.23), representing a change of +2.9% in EUR (+4.7% in CHF) since February 28, 2026, and of -3.1% respectively for the financial year 2025/2026 (in EUR, i [ … ]
Tue, 14.04.2026
tick Trading Software AG
tick Trading Software AG raises forecast for the current business year 2025/2026
Düsseldorf, April 14, 2026 – tick Trading Software AG (ISIN: DE000A35JS99; tick-TS AG) is raising its forecast for the current 2025/2026 business year. The provider of software for securities trading and settlement now expects a net income of between EUR 800,000 and [ … ]
Tue, 14.04.2026
PolyPeptide Group
Media release – ad hoc announcement pursuant to Art. 53 LR
PolyPeptide Group AG takes note of market rumors and speculation
Baar, 14 April 2026 – PolyPeptide Group AG (SIX: PPGN) (“PolyPeptide” or the “Company”), a specialized global CDMO for peptide-based active pharmaceutical ingredients, takes note of recent market speculation and media report [ … ]
